Aims The well-known limitations of vitamin K antagonists (VKA) led to development of new
oral anticoagulants (NOAC) in non-valvular atrial fibrillation (NVAF). The aim of this meta …

Aim: To compare real-world effectiveness/safety of non-vitamin K antagonist oral
anticoagulants and vitamin K antagonists among patients with non-valvular atrial fibrillation …

Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …

Introduction: Numerous real-world studies have compared non-vitamin K antagonist oral
anticoagulants (NOACs) with vitamin K antagonists (VKAs) in patients with non-valvular …

Introduction: Choosing between different non-vitamin K antagonist oral anticoagulants
(NOACs) in non-valvular atrial fibrillation (NVAF) is difficult due to the absence of head to …

The choice of an oral anticoagulant (OAC) for patients with nonvalvular atrial fibrillation
(NVAF) is a major and complex clinical decision taking into account the individual risk …

Introduction: Several comparative real-world effectiveness studies on direct oral
anticoagulants (DOACs) have been conducted, but an overview of the available evidence …

Purpose The findings from the observational studies comparing the effectiveness and safety
of non–vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists …

Background—Novel oral anticoagulants (NOACs) have been proposed as alternatives to
vitamin K antagonists for the prevention of stroke and systemic embolism in patients with …

Aims After non-vitamin K antagonist (VKA) oral anticoagulation agents (NOAC) have been
approved for thrombo-embolic prophylaxis in non-valvular atrial fibrillation (NVAF) …